# Exor

## HALF-YEAR 2024 RESULTS

25 SEPTEMBER 2024

Certain statements and information contained in this presentation that are not statements or information of historical fact constitute forward-looking statements, notwithstanding that such statements are not specifically identified. These forward-looking statements may include statements regarding our (or our investee companies') plans, objectives, goals, strategies, future events, future revenue or performance, financing needs, plans or intentions relating to acquisitions, investments or capital expenditures, business trends or other information that is not historical information. These statements may include terminology such as "may", "will", "expect", "could", "should", "intend", "estimate", "anticipate", "believe", "remain", "on track", "design", "target", "objective", "goal", "forecast", "projection", "outlook", "prospects", "plan", "intend", or similar terminology. Forward-looking statements are related to future, not past, events and are not guarantees of future performance. These statements are based on current expectations, assumptions and projections about future events and, by their nature, address matters that are, to different degrees, uncertain and are subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future, and, as such, undue reliance should not be placed on them. Actual results may differ materially from those expressed in such statements as a result of a variety of factors, including among others:

- changes in general economic, financial and market conditions and other changes in business conditions;
- changes in commodity prices, the level of demand and financial performance of the major industries our portfolio companies serve; and
- changes in regulations and institutional framework

These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements such as those included in Exor's Annual Report 2023, including those set

forth under the heading "Risk Factors". These risks and uncertainties, as well as other risks of which we are not aware or which we currently do not believe to be material, may cause our actual future results to be materially different than those expressed in our forward-looking statements.

Investors and shareholders are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements speak only as of the date they are made. All forward looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. Exor undertakes no obligation to update or revise its outlook or forward-looking statements, whether as a result of new developments or otherwise. Exor expressly disclaims and does not assume any liability in connection with any inaccuracies in any of these forward-looking statements or in connection with any use by any party of such forward-looking statements.

Names, organizations and company names referred to may be the trademarks of their respective owners.

This presentation does not represent investment advice neither a solicitation, nor a recommendation nor an invitation, nor an offer for the purchase or sale of financial products and/or of any kind of financial services as contemplated by the laws in any country or state.

- NAV of €38.3 billion (€178.46/share) at 30 June 2024, up from €35.4 billion (€164.02/share) at 1 January 2024
- Net debt was €3.7 billion at 30 June 2024, down from €4.0 billion at 1 January 2024
- LTV ratio of 9% at 30 June 2024, down from 10% at 1 January 2024
- Investment Entity reporting under IFRS 10 applied from 1 January 2024

Exor Builds Great Companies With Great People

### PERFORMANCE OF NAV PER SHARE OVER BENCHMARK

	EXOR'S PERFORMANCE: HALF-YEAR 2024				PERFORMANCE SINCE INCEPTION % increase (decrease)						
125				YEAR	TSR	1 - NAV/SHARE (€)	2 - MSCI (€)	DELTA (1-2)			
120		m		2009	126.8	87.1	37.8	49.3			
		M.		2010	85.7	44.2	17.2	27.0			
115	M			2011	(36.1)	(23.8)	(4.5)	(19.3)			
	$\sim$			2012	24.7	19.3	11.4	7.9			
110		m m		2013	54.3	15.8	18.7	(2.9)			
	m			2014	19.1	14.5	17.2	(2.7)			
105				2015	24.6	20.8	8.3	12.5			
	A V			2016	(1.6)	13.2	8.5	4.7			
100	sh s			2017	25.5	37.9	5.5	32.4			
-	W			2018	(7.0)	(9.5)	(5.9)	(3.6)			
95				2019	47.2	37.1	27.5	9.6			
Dec-23		ar-24	Jun-24	2020	(3.3)	3.5	4.6	(1.1)			
	Exor NAV per shar	e — MSCI World Index		2021	20.0	29.7	29.3	0.4			
		1H 2024		2022	(12.9)	(7.6)	(14.2)	6.6			
	——————————————————————————————————————	0.004		2023	33.2	32.7	17.6	15.1			
	Exor's NAV/share	8.8%		1H 2024	8.4	8.8	14.2	(5.4)			
	MSCI World Index	14.2%		CAGR	20.3	18.6	11.8	6.8			

Note: data in 2009 starts from March 1<sup>st</sup>, the date before Exor's listing.

### **DRIVERS OF CHANGE IN GAV**

in € billion	GAV (A+B+C)	Listed Companies	Unlisted Companies	Companies (A)	Lingotto Funds	Ventures	Investments (B)	Others <sup>1</sup> (C)
1 January 2024	39.7	31.2	3.0	34.2	2.1	0.7	2.8	2.7
Investment (Disposal)	1.3	0.6	0.1	0.8	-	0.0	0.1	0.4
Change in Value	2.0	2.0	(0.0)	1.9	0.2	0.0	0.3	(0.2)
Reclassification	-	0.4	-	0.4	-	-	-	(0.4)
30 June 2024	43.1	34.2	3.1	37.3	2.4	0.8	3.1	2.6

#### Gross Asset Value (GAV) performance drivers

Notes: Numbers may not add due to rounding.

1) At 30 June 2024 Others include: Liquidity ( $\in$ 1.4 billion, of which  $\in$ 1.0 billion cash, cash equivalents and financial assets and  $\in$ 0.4bn listed securities), Reinsurance vehicles ( $\in$ 0.6 billion) and Other assets ( $\in$ 0.6 billion).

Exor
------

in € million	1 JAN 2024	Reclassification	Investment (Disposal)	Change in Value	30 JUN 2024	Net Change
Ferrari	13,562	-	-	3,355	16,917	3,355
Stellantis	9,505	-	-	(1,204)	8,301	(1,204)
Philips <sup>1</sup>	2,937	-	622	323	3,882	945
CNH	4,066	-	-	(594)	3,472	(594)
lveco	598	-	-	170	768	170
Juventus	542	-	14	(7)	549	7
Clarivate <sup>2,3</sup>	-	433	-	(75)	358	358
Listed Companies	31,210	433	636	1,968	34,247	3,037

1) The column investment (disposal) includes 4,872,647 shares (€121 million) received as dividend paid in shares. The change in value over the period includes €403 million recognized in other comprehensive income reserve until the significant influence was achieved.

2) During the first half of 2024, Exor became a long-term investor in Clarivate with a board seat. As a result, Exor accounted for Clarivate at FVTPL from that date. From a management presentation point of view, Exor reclassified Clarivate from "Others" to "Companies".

3) The change in value over the period includes a  $\in$ 3 million of positive exchange differences on translation.

### **PERFORMANCE OF UNLISTED COMPANIES**

in € million	1 JAN 2024	Reclassification	Investment (Disposal)	Change in Value	30 JUN 2024	Net Change
Institut Mérieux <sup>1</sup>	844	-	-	(27)	817	(27)
Christian Louboutin	700	-	-	(125)	575	(125)
Via Transportation	514	-	-	17	531	17
The Economist	384	-	-	23	407	23
Welltec	280	-	-	49	329	49
Tag Energy <sup>2</sup>	100	-	72	-	172	72
Nuo	42	-	34	8	84	42
Lifenet	71	-	8	-	79	8
GEDI	68	-	10	-	78	10
Casavo	13	-	-	-	13	-
Shang Xia	0	-	-	-	0	-
Unlisted Companies	3,016	-	124	(55)	3,085	69

1) Includes Exor's commitment to purchase 341,171 shares of Institut Mérieux for €555 million to reach a shareholding of 10%.

2) Owned through the holding company TagHolding.

Exor

### **PERFORMANCE OF INVESTMENTS AND OTHERS**

Exor
------

in € million	1 JAN 2024	Reclassification	Investment (Disposal)	Change in Value	Translation Effect	30 JUN 2024	Net Change
Lingotto Funds	2,099	-	23	228	-	2,350	251
Ventures	679	-	52	53	-	784	105
Investments	2,778	-	75	281	-	3,134	356
Reinsurance Vehicles	802	-	(287)	54	24	593	209
Other Assets	473	-	101	17	-	591	118
Listed Securities	1,142	(433)	(74)	(218)	14	431	(711)
Cash and cash equivalents and financial assets	318	-	691	1	-	1,010	692
Others	2,735	(433)	431	(146)	38	2,625	(110)

### **NET FINANCIAL POSITION**

#### € in million

NET FINANCIAL POSITION – 1 JAN 2024	(3,968)
Dividends Inflow <sup>1</sup>	987
Asset Disposals	372
Amount Invested <sup>2</sup>	(815)
Buyback Exor Shares	(125)
Dividends Paid by Exor	(99)
Other Changes	(57)
NET CHANGE	263
NET FINANCIAL POSITION – 30 JUN 2024	(3,705)

Exor

- Received ~€1.0bn dividends from companies
- Cashed-in ~€0.4bn proceeds from reinsurance vehicle redemptions and sales of listed securities
- Invested ~€0.9bn mainly in Companies, Lingotto and Ventures
- Bought back €0.13bn in shares
- Paid €0.1bn ordinary dividend to shareholders

1) Stellantis (€697 million), CNH (€160 million), Ferrari (€108 million), Iveco (€16 million) and Other (€6 million).

2) Includes Philips (€622 million), TagEnergy (€72 million), Exor Ventures/Seeds (€52 million), Nuo (€34 million), Lingotto Funds (€23 million), Juventus (€14 million), among others.

### **INVESTMENT ENTITY REPORTING APPLIED FROM 1 JANUARY 2024**

#### **PRESENTATION OF THE FINANCIAL STATEMENTS UNDER IFRS 10**

#### Consolidated Statement of Financial Position

Total Equity and Liabilities	
Total Liabilities	
Other liabilities	
Tax payables	Other Liabilities
Trade payables	
Other financial liabilities	GIUSS DEDI
Borrowings	Gross Debt
Total Equity	
Equity attributable to owners of the parent	NAV
Total Assets	1
Cash and cash equivalents	
Current tax assets	
Other assets	
Deferred tax assets	GAV
Financial assets	0.01/
Other investments at FVTPL	
Equity investments at FVTOCI	
Equity investments at FVTPL	
Property, plant and equipment	

#### Consolidated Income Statement

Dividend income Change in fair value of investment activities Net revenues General and administrative expenses Financial income/expenses **Profit (loss) before taxes** Income taxes **Profit (loss) for the period** 

#### Change in consolidation

- Portfolio companies are deconsolidated and accounted for at fair value, with changes recognized in the income statement
- Subsidiaries that provide support services to Exor NV related to the management of investments continue to be consolidated on a line-by-line basis

#### Comparison with previous period

- In accordance with IFRS, figures at 30 June 2023 have not been restated
- To facilitate the comparability of measures, NAV and its components at 30 June 2024 are compared to 1 January 2024

#### Impact on financial statements

 One-off positive impact in the income statement of €11.8 billion

Exor

### **PROFIT FOR THE PERIOD**

	Six months e	nded 30 June
in € million	2024	<b>2023</b> <sup>1</sup>
Dividend Income <sup>2</sup>	1,108	10
Change in Fair Value of Investment Activities	1,882	-
Change in Fair Value of Investment Activities (one-off) <sup>3</sup>	12,150	-
Profit from Investments in Subsidiaries and Associates	-	1,981
Profit from Investments at FVTPL and FVTOCI	-	146
General and Administrative Expenses	(22)	(26)
Financial Expenses	(24)	46
Other Expenses (one-off) <sup>4</sup>	(374)	-
Profit (Loss) before Taxes	14,720	2,157
Income Taxes	(25)	-
Profit (Loss) for the Period	14,695	2,157


## Total one-off positive impact of €11.8 billion, of which:

- €12.1 billion resulting from the difference between the net carrying amount of investments previously consolidated or accounted for using the equity method and their fair value
- -€374 million resulting from the reversal to the income statement of the OCI reserves of the entities deconsolidated and no longer accounted for at equity

- 2) Including Stellantis (€697 million), CNHI (€160 million), Philips (€121 million paid in shares), Ferrari (€108 million), Iveco (€16 million) and other (€6 million).
- 3) One-off item deriving from the application of the investment entity exemption.

<sup>1)</sup> Data as previously reported using the shortened consolidation criterion.

<sup>4)</sup> One-off item related to the reversal in the income statement of the OCI reserves of the entities deconsolidated following the investment entity adoption.



#### **UPCOMING EVENTS**

Exor's Investor and Analyst Call will be held virtually on 26 November 2024

